Abiopharma

Harpoon Therapeutics Inc (was acquisited by Merck (NYSE:MRK) on 11/03/2024) (HARP) Announces Clinical Trial Update Harpoon Therapeutics Inc (was acquisited by Merck (NYSE:MRK) on 11/03/2024) (HARP) provided an update on its clinical development programs. Clinical Development Highlights:

• Drug Program: period
• Collaboration: Harpoon Therapeutics, Inc.
  • targeting T-cell engager derived from the TriTAC® platform. HPN328 contains 3 binding domains, engineered to redirect T cells to kill DLL3-expressing cancer cells: anti-DLL3 for target engagement, anti-albumin for half-life extension, and anti-CD3 for T-cell engagement. The information in this Item 7.01 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934